<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02246647</url>
  </required_header>
  <id_info>
    <org_study_id>14-002382</org_study_id>
    <nct_id>NCT02246647</nct_id>
  </id_info>
  <brief_title>Biomarkers for Intestinal Permeability in Patients With Constipation</brief_title>
  <official_title>Biomarkers for Intestinal Permeability in Patients With Functional Lower Gastrointestinal Disorders Associated With Constipation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our overall objective with this study is firstly to provide a comprehensive assessment of
      intestinal permeability, mucosal barrier function using existing biomarkers and secondly to
      explore novel biomarkers for measuring intestinal permeability in patients with constipation
      predominant Irritable Bowel Syndrome (IBS-C).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to determine the differences in permeability in IBS-C in comparison with healthy
      volunteers, the following will be determined: differences in in vivo small intestinal and
      colonic permeability, differences in small intestinal and colonic mucosal barrier function,
      differences in effects of fecal supernatants on barrier function of T84 monolayers, and
      differences in novel biomarkers for intestinal permeability
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>8-24 hr cumulative excretion of mannitol.</measure>
    <time_frame>Baseline to 1 month</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Intestinal Diseases</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and (non-radioactive) 13C labeled mannitol, 100 mg and sucralose, 50 mg) in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBS-C</arm_group_label>
    <description>Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and (non-radioactive) 13C labeled mannitol, 100 mg and sucralose, 50 mg) in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saccharides</intervention_name>
    <description>saccharides will be compared in IBS-C vs healthy participants</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>IBS-C</arm_group_label>
    <other_name>mannitol</other_name>
    <other_name>lactulose</other_name>
    <other_name>sucralose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>esophagogastroduodenoscopy</intervention_name>
    <description>duodenal biopsies will be collected from IBS-C volunteers and healthy volunteers</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>IBS-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>flexible sigmoidoscopy</intervention_name>
    <description>colonic biopsies will be collected from IBS-C volunteers and healthy volunteers</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>IBS-C</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Colonic Biopsies Duodenal Biopsies Duodenal Aspirate Blood Urine Fecal
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        IBS-Constipation cases and healthy volunteers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        A. 18 - 65 years old B. IBS-C by Rome III criteria (for IBS-C participants) C. No abdominal
        surgery (except appendectomy and cholecystectomy)

        Exclusion criteria:

        A. History of Inflammatory Bowel Disease (IBD) , microscopic colitis or celiac disease B.
        Use of tobacco products within the past 6 months C. Use of NSAIDs or aspirin within the
        past week D. Use of oral corticosteroids within the previous 6 weeks E. Ingestion of
        artificial sweeteners such as SplendaTM (sucralose), Nutrasweet TM(aspartame), lactulose or
        mannitol 2 days before the study begins, e.g., foods to be avoided are sugarless gums or
        mints and diet soda F. Ingestion of any prescription, over the counter, or herbal
        medications which can affect gastrointestinal transit 7 days before study begins

          1. Any treatment specifically taken for IBS, including loperamide, cholestyramine,
             alosetron

          2. Drugs with a known pharmacological activity at 5-HT4, 5-HT2b or 5-HT3 receptors (e.g,
             tegaserod, ondansetron, tropisetron, granisetron, dolasetron, mirtazapine);

          3. All narcotics (e.g, codeine, morphine, and propoxyphene, either alone or in
             combination)

          4. Anti-cholinergic agents (e.g, dicyclomine, hyoscyamine, propantheline).

          5. Ultram

          6. GI preparations

               -  Anti-nausea agents (e.g, trimethobenzamide, promethazine, prochlorperazine,
                  dimenhydrinate, hydroxyzine)

               -  Osmotic laxative agents (e.g, lactulose, sorbitol or PEG solutions as Miralax and
                  Glycolax)

               -  Prokinetic agents (e.g, cisapride, metoclopramide, itopride, domperidone);

          7. Antimuscarinics;

          8. Peppermint oil;

          9. Systemic antibiotics, rifaximin, metronidazole. G. Bleeding disorders or medications
             that increase risk of bleeding from mucosal biopsies.

        H. Score &gt; 8 for anxiety or depression on Hospital anxiety and depression scale.

        I. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhusudan Grover, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Sundt</last_name>
      <phone>507-293-4234</phone>
      <email>sundt.wendy@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Madhusudan Grover</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2014</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Madhusudan (Madhu) Grover, MBBS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 31, 2017</submitted>
    <returned>January 31, 2018</returned>
    <submitted>February 23, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

